# Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age

> **NCT06643442** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sebastiano Lava** · enrollment: 12 (estimated)

## Conditions studied

- DMD-associated Dilated Cardiomyopathy

## Interventions

- **DRUG:** Empagliflozin Tablets

## Key facts

- **NCT ID:** NCT06643442
- **Lead sponsor:** Sebastiano Lava
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643442, "Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06643442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*